Details for New Drug Application (NDA): 021275
✉ Email this page to a colleague
The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
Summary for 021275
Tradename: | LUMIGAN |
Applicant: | Abbvie |
Ingredient: | bimatoprost |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021275
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.03% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Mar 16, 2001 | TE: | RLD: | Yes |
Expired US Patents for NDA 021275
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 021275-001 | Mar 16, 2001 | 5,688,819 | ⤷ Subscribe |
Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 021275-001 | Mar 16, 2001 | 8,017,655 | ⤷ Subscribe |
Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 021275-001 | Mar 16, 2001 | 6,403,649 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription